Subcutaneous Semaglutide Significantly Reduces Atrial Fibrillation Risk Compared to Placebo and Tirzepatide
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis.
Abstract
Subcutaneous semaglutide significantly reduced new-onset atrial fibrillation risk (RR 0.82 vs placebo; RR 0.57 vs tirzepatide) in a network meta-analysis.
TitrateLab articles covering Tirzepatide
Written by TitrateLab, separately from the study summarized above.
